- Home
- Primary Angle Closure Glaucoma Market
Global Primary Angle-Closure Glaucoma Market - Industry Trends and Forecast to 2028
- Published Date: September, 2022 | Report ID: CLS-261 | No of pages: 257 | Format:
Global primary angle-closure glaucoma market is projected to register a CAGR of 6.1% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028.
Market Segmentation:
Global Primary Angle-Closure Glaucoma Market, By Disease Type (Acute Angle-Closure Glaucoma and Chronic Angle-Closure Glaucoma), Type (Diagnosis and Treatment), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers and Others), Distribution Channel (Direct Tender, Retail Sales and Others), Country (U.S., Canada, Mexico, Germany, France, Italy U.K., Spain, Russia, Austria, Netherlands, Hungary, Poland, Switzerland, Turkey, Norway, Lithuania, Ireland, Rest of Europe, Japan, China, India, Australia, Singapore, South Korea, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, South Africa, Egypt, Saudi Arabia, Israel, UAE, Kuwait, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Some of the major factors contributing to the growth of the global primary angle-closure glaucoma market are:
Increasing prevalence of angle-closure glaucoma
Advancement in surgical treatment of the disease
Market Players:
The key market players for the global primary angle-closure glaucoma market are listed below:
Johnson & Johnson Vision Care, Inc. (a subsidiary of Johnson & Johnson Services Inc.)
Aurolab
New World Medical, Inc.
Sight Sciences, Inc.
NIDEK CO., LTD
BVI
MicroSurgical Technology
Allergan (a subsidiary of AbbVie Inc.)
Bausch & Lomb Incorporated (a subsidiary of Bausch Health Companies Inc.)
Oertli Instrumente AG
Medisonic Equipments Pvt. Ltd.
Omni Lens
APPASAMY ASSOCIATES
NOVAEYE MEDICAL
ZEISS International
Alcon Inc.
LIGHTMED
Luneau Technology USA
Reichert, Inc. (a business unit of Ametek Inc.)
NEW VISION
TABLE OF CONTENT
TABLE OF CONTENTS 1 INTRODUCTION 32 1.1 OBJECTIVES OF THE STUDY 32 1.2 MARKET DEFINITION 32 1.3 OVERVIEW OF GLOBAL PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET 32 1.4 LIMITATIONS 34 1.5 MARKETS COVERED 35 2 MARKET SEGMENTATION 37 2.1 MARKETS COVERED 37 2.2 GEOGRAPHICAL SCOPE 38 2.3 YEARS CONSIDERED FOR THE STUDY 39 2.4 CURRENCY AND PRICING 39 2.5 DBMR TRIPOD DATA VALIDATION MODEL 40 2.6 MULTIVARIATE MODELLING 43 2.7 TYPE LIFELINE CURVE 43 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 44 2.9 DBMR MARKET POSITION GRID 45 2.10 MARKET END USER COVERAGE GRID 46 2.11 VENDOR SHARE ANALYSIS 47 2.12 SECONDARY SOURCES 48 2.13 ASSUMPTIONS 48 3 EXECUTIVE SUMMARY 49 4 EPIDEMIOLOGY 54 5 REGULATORY FRAMEWORK 55 6 PIPELINE ANALYSIS 58 7 MARKET OVERVIEW 59 7.1 DRIVERS 61 7.1.1 INCREASING PREVALENCE OF ANGLE-CLOSURE GLAUCOMA 61 7.1.2 INCREASING WOMEN POPULATION 61 7.1.3 RISE IN GERIATRIC POPULATION 62 7.1.4 ADVANCEMENTS IN SURGICAL TREATMENT OF THE DISEASE 62 7.1.5 INCREASED ECONOMIC BURDEN 63 7.2 RESTRAINTS 63 7.2.1 HIGH SURGICAL COSTS OF PACG 63 7.2.2 INADEQUATE REIMBURSEMENT SCENARIO 64 7.2.3 DELAYED AND MISDIAGNOSIS OF PACG 64 7.3 OPPORTUNITIES 65 7.3.1 INCREASING GOVERNMENT INITIATIVES TOWARDS GLAUCOMA 65 7.3.2 RECENT APPROVAL BY GOVERNING BODIES 66 7.3.3 INCREASING INCIDENCES IN EMERGING MARKET 66 7.3.4 RAPID TRANSITION FROM PACG MEDICATION TO SURGERIES 66 7.4 CHALLENGES 67 7.4.1 RISKS ASSOCIATED WITH SURGICAL PROCEDURES 67 7.4.2 LACK OF SKILLED PROFESSIONALS WITH ADEQUATE KNOWLEDGE 68 7.4.3 LIMITED ACCESS TO TREATMENT 68 8 IMPACT OF COVID-19 ON GLOBAL PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET 69 8.1 IMPACT ON PRICE 69 8.2 IMPACT ON DEMAND 69 8.3 IMPACT ON SUPPLY CHAIN 70 8.4 STRATEGIC DECISION BY MANUFACTURERS 70 8.5 CONCLUSION 71 9 GLOBAL PRIMARY ANGLE CLOSURE GLAUCOMA MARKET, BY DISEASE TYPE 72 9.1 OVERVIEW 73 9.2 ACUTE ANGLE-CLOSURE GLAUCOMA MARKET 76 9.3 CHRONIC ANGLE-CLOSURE GLAUCOMA MARKET 76 10 GLOBAL PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 78 10.1 OVERVIEW 79 10.2 DIAGNOSIS 82 10.2.1 PRIMARY TEST 83 10.2.1.1 GONIOSCOPY EXAMINATION 83 10.2.1.2 SLIT-LAMP EXAMINATION 83 10.2.1.3 AUTOMATIC STATIC PERIMETRY 83 10.2.2 SECONDARY TEST 83 10.2.2.1 ULTRASOUND BIOMICROSCOPY 84 10.2.2.2 ANTERIOR SEGMENT OPTICAL COHERENCE TOMOGRAPHY (OCT) 84 10.2.2.3 RETINAL OCT 84 10.2.2.4 FUNDOSCOPY 84 10.2.2.5 OTHERS 85 10.3 TREATMENT 85 10.3.1 SURGICAL IRIDECTOMY 87 10.3.2 TRABECULECTOMY 87 10.3.3 MICRO INVASIVE GLAUCOMA TECHNIQUE (MIGS) 87 10.3.4 GONIOTOMY 88 10.3.5 OTHERS 88 11 GLOBAL PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER 89 11.1 OVERVIEW 90 11.2 HOSPITALS 93 11.3 AMBULATORY SURGICAL CENTERS 93 11.4 SPECIALTY CLINICS 94 11.5 OTHERS 95 12 GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 96 12.1 OVERVIEW 97 12.2 DIRECT TENDER 100 12.3 RETAIL SALES 100 12.4 OTHERS 101 13 GLOBAL PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY GEOGRAPHY 102 13.1 OVERVIEW 103 13.2 NORTH AMERICA 108 13.2.1 U.S. 113 13.2.2 CANADA 115 13.2.3 MEXICO 117 13.3 EUROPE 119 13.3.1 GERMANY 125 13.3.2 FRANCE 127 13.3.3 ITALY 129 13.3.4 U.K. 131 13.3.5 SPAIN 133 13.3.6 RUSSIA 135 13.3.7 AUSTRIA 137 13.3.8 NETHERLANDS 139 13.3.9 HUNGARY 141 13.3.10 POLAND 143 13.3.11 SWITZERLAND 145 13.3.12 TURKEY 147 13.3.13 NORWAY 149 13.3.14 LITHUANIA 151 13.3.15 IRELAND 153 13.3.16 REST OF EUROPE 155 13.4 ASIA-PACIFIC 156 13.4.1 JAPAN 162 13.4.2 CHINA 164 13.4.3 INDIA 166 13.4.4 AUSTRALIA 168 13.4.5 SINGAPORE 170 13.4.6 SOUTH KOREA 172 13.4.7 MALAYSIA 174 13.4.8 THAILAND 176 13.4.9 INDONESIA 178 13.4.10 PHILIPPINES 180 13.4.11 VIETNAM 182 13.4.12 REST OF ASIA-PACIFIC 184 13.5 SOUTH AMERICA 185 13.5.1 BRAZIL 190 13.5.2 ARGENTINA 192 13.5.3 PERU 194 13.5.4 REST OF SOUTH AMERICA 196 13.6 MIDDLE EAST AND AFRICA 197 13.6.1 SOUTH AFRICA 203 13.6.2 EGYPT 205 13.6.3 SAUDI ARABIA 207 13.6.4 ISRAEL 209 13.6.5 UAE 211 13.6.6 KUWAIT 213 13.6.7 REST OF MIDDLE EAST AND AFRICA 215 14 GLOBAL PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: COMPANY LANDSCAPE 216 14.1 COMPANY SHARE ANALYSIS: GLOBAL 216 14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 217 14.3 COMPANY SHARE ANALYSIS: EUROPE 218 14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 219 15 SWOT 220 16 COMPANY PROFILES 221 16.1 JOHNSON & JOHNSON VISION CARE, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.) 221 16.1.1 COMPANY SNAPSHOT 221 16.1.2 REVENUE ANALYSIS 221 16.1.3 COMPANY SHARE ANALYSIS 222 16.1.4 PRODUCT PORTFOLIO 222 16.1.5 RECENT DEVELOPMENTS 222 16.2 BAUSCH & LOMB INCORPORATED (A SUBSIDIARY OF BAUSCH HEALTH COMPANIES INC.) 224 16.2.1 COMPANY SNAPSHOT 224 16.2.2 REVENUE ANALYSIS 224 16.2.3 COMPANY SHARE ANALYSIS 225 16.2.4 PRODUCT PORTFOLIO 225 16.2.5 RECENT DEVELOPMENTS 225 16.3 ALCON INC. 226 16.3.1 COMPANY SNAPSHOT 226 16.3.2 REVENUE ANALYSIS 226 16.3.3 COMPANY SHARE ANALYSIS 227 16.3.4 PRODUCT PORTFOLIO 227 16.3.5 RECENT DEVELOPMENTS 227 16.4 ZEISS INTERNATIONAL 229 16.4.1 COMPANY SNAPSHOT 229 16.4.2 REVENUE ANALYSIS 229 16.4.3 COMPANY SHARE ANALYSIS 230 16.4.4 PRODUCT PORTFOLIO 230 16.4.5 RECENT DEVELOPMENTS 230 16.5 NOVA EYE MEDICAL LIMITED 232 16.5.1 COMPANY SNAPSHOT 232 16.5.2 REVENUE ANALYSIS 232 16.5.3 PRODUCT PORTFOLIO 233 16.5.4 RECENT DEVELOPMENTS 233 16.6 NIDEK CO., LTD 234 16.6.1 COMPANY SNAPSHOT 234 16.6.2 PRODUCT PORTFOLIO 234 16.6.3 RECENT DEVELOPMENTS 234 16.7 ALLERGAN (A SUBSIDIARY OF ABBVIE INC.) 236 16.7.1 COMPANY SNAPSHOT 236 16.7.2 REVENUE ANALYSIS 236 16.7.3 PRODUCT PORTFOLIO 237 16.7.4 RECENT DEVELOPMENT 237 16.8 APPASAMY ASSOCIATES 238 16.8.1 COMPANY SNAPSHOT 238 16.8.2 PRODUCT PORTFOLIO 238 16.8.3 RECENT DEVELOPMENT 238 16.9 AUROLAB 239 16.9.1 COMPANY SNAPSHOT 239 16.9.2 PRODUCT PORTFOLIO 239 16.9.3 RECENT DEVELOPMENT 239 16.10 BVI 240 16.10.1 COMPANY SNAPSHOT 240 16.10.2 PRODUCT PORTFOLIO 240 16.10.3 RECENT DEVELOPMENTS 240 16.11 LIGHTMED 241 16.11.1 COMPANY SNAPSHOT 241 16.11.2 PRODUCT PORTFOLIO 241 16.11.3 RECENT DEVELOPMENTS 241 16.12 LUNEAU TECHNOLOGY USA 242 16.12.1 COMPANY SNAPSHOT 242 16.12.2 PRODUCT PORTFOLIO 242 16.12.3 RECENT DEVELOPMENT 242 16.13 MEDISONIC EQUIPMENTS PVT. LTD. 243 16.13.1 COMPANY SNAPSHOT 243 16.13.2 PRODUCT PORTFOLIO 243 16.13.3 RECENT DEVELOPMENT 243 16.14 MICROSURGICAL TECHNOLOGY 244 16.14.1 COMPANY SNAPSHOT 244 16.14.2 PRODUCT PORTFOLIO 244 16.14.3 RECENT DEVELOPMENTS 244 16.15 NEW VISION 245 16.15.1 COMPANY SNAPSHOT 245 16.15.2 PRODUCT PORTFOLIO 245 16.15.3 RECENT DEVELOPMENTS 245 16.16 NEW WORLD MEDICAL, INC. 247 16.16.1 COMPANY SNAPSHOT 247 16.16.2 PRODUCT PORTFOLIO 247 16.16.3 RECENT DEVELOPMENTS 247 16.17 OERTLI INSTRUMENTE AG 248 16.17.1 COMPANY SNAPSHOT 248 16.17.2 PRODUCT PORTFOLIO 248 16.17.3 RECENT DEVELOPMENTS 248 16.18 OMNI LENS 249 16.18.1 COMPANY SNAPSHOT 249 16.18.2 PRODUCT PORTFOLIO 249 16.18.3 RECENT DEVELOPMENT 249 16.19 REICHERT, INC. (A BUSINESS UNIT OF AMETEK.INC.) 250 16.19.1 COMPANY SNAPSHOT 250 16.19.2 REVENUE ANALYSIS 250 16.19.3 PRODUCT PORTFOLIO 251 16.19.4 RECENT DEVELOPMENTS 251 16.20 SIGHT SCIENCES, INC. 252 16.20.1 COMPANY SNAPSHOT 252 16.20.2 PRODUCT PORTFOLIO 252 16.20.3 RECENT DEVELOPMENTS 252 17 QUESTIONNAIRE 254 18 RELATED REPORTS 257Segmentation
Short Description Global Primary Angle-Closure Glaucoma Market, By Disease Type (Acute Angle-Closure Glaucoma and Chronic Angle-Closure Glaucoma), Type (Diagnosis and Treatment), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers and Others), Distribution Channel (Direct Tender, Retail Sales and Others), Country (U.S., Canada, Mexico, Germany, France, Italy U.K., Spain, Russia, Austria, Netherlands, Hungary, Poland, Switzerland, Turkey, Norway, Lithuania, Ireland, Rest of Europe, Japan, China, India, Australia, Singapore, South Korea, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, South Africa, Egypt, Saudi Arabia, Israel, UAE, Kuwait, Rest of Middle East and Africa) Industry Trends and Forecast to 2028 Market Definition: Glaucoma is a group of eye conditions that damage the optic nerve and the proper functioning of the optic nerve is necessary for good vision. This damage is often caused by abnormally high pressure in the eye. The primary angle-closure (PAC) is defined as appositional or synechial closure of the anterior chamber angle which can lead to aqueous outflow obstruction and raised IOP in the absence of glaucomatous optic neuropathy. Market Segmentation: The primary angle-closure glaucoma market is segmented on the basis of the disease type, type, end user and distribution channel. On the basis of disease type, the primary angle-closure glaucoma market is segmented into acute angle-closure glaucoma and chronic angle-closure glaucoma On the basis of type, the primary angle-closure glaucoma market is segmented into diagnosis and treatment On the basis of end user, the primary angle-closure glaucoma market is segmented into hospitals, specialty clinics, ambulatory surgical centers and others On the basis of distribution channel, the primary angle-closure glaucoma market is segmented into direct tender, retail sales and others Market Players The key market players for the global primary angle-closure glaucoma market are listed below: Johnson & Johnson Vision Care, Inc. (a subsidiary of Johnson & Johnson Services Inc.) Aurolab New World Medical, Inc. Sight Sciences, Inc. NIDEK CO., LTD BVI MicroSurgical Technology Allergan (a subsidiary of AbbVie Inc.) Bausch & Lomb Incorporated (a subsidiary of Bausch Health Companies Inc.) Oertli Instrumente AG Medisonic Equipments Pvt. Ltd. Omni Lens APPASAMY ASSOCIATES NOVAEYE MEDICAL ZEISS International Alcon Inc. LIGHTMED Luneau Technology USA Reichert, Inc. (a business unit of Ametek Inc.) NEW VISIONMethodology
Why Choose Us
24 * 7 Access to Analyst :
Get your pre and post sales queries resolved by our Subject matter experts.
Customization :
We will assist you to customize the report to fit your research needs.
Assured Quality :
Our prime focus is to provide qualitative and accurate data.
Free sample report :
Feel free to order a sample report before purchase.
Security :
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.